Hello, September! 

Spring has finally arrived following an eventful winter.
July saw the Equine Veterinary Association host yet another very successful Bain Fallon Conference in Melbourne. We had the pleasure of meeting an array of wonderful vets and exhibitors while managing to attend some very educational lectures. All in all, a great week was had, well done to all involved and we look forward to seeing you next year!

We have seen the Australian Eventing team take home the bronze medal from Rio –
congratulations from all here at Biopharm Australia!
Winter also brought news of a ban on greyhound racing, which came as quite a surprise to most and continues to be a topic of much debate as the weeks go on.
In other racing news, we can look forward to the spring carnival and all the excitement it brings, for horse and fashion enthusiasts alike! Racing and training will no doubt take their toll on horses once again this season, so be sure to get behind Cartrophen Equine Forte to help manage any traumatic joint injury and osteoarthritis that may arise.

Following the success of our winter Power Bank Promotion, we will soon have some new spring giveaways up and running, so watch this space!
We are also happy to announce the launch of our new Cartrophen website.

Come and visit us on



Cartrophen is safe to give weekly at the prescribed dose continuously. This has been proven with detailed toxicity studies in the dog. The recommended treatment of once per week for 4 weeks can be repeated:

When the symptoms return

As a routine treatment every 6-12 months in dogs with established osteoarthritis

Monthly booster injections are recommended by some veterinarians in severe osteoarthritis.

These courses can be repeated as often, and for as long as, the clinician believes they are useful. Osteoarthritis presents as a complex. Its presentation and course is a result of a number of factors and its clinical management is determined by you, the clinician. These factors can be listed as:

The severity of the inciting cause such as a deformity or injury (For example ruptured ligament or tendon and fractures)

The symptoms will vary between mild, moderate and severe

The amount of damage to the joint will vary between mild, moderate and severe

The osteoarthritic problem may impact the quality of life of the pet to various degrees

The dog may be young, middle or elderly. This will determine the dose regime.

In young animals the goal could be to assist healing or retard the progress of OA. In this situation routine yearly courses can be given. In older animals, existing osteoarthritis can be treated with regular injections or monthly booster doses.



Cartrophen acts by treating the underlying metabolic defects of osteoarthritis, though there may not be dramatic clinical improvement. Many patients do show dramatic improvement after the first dose, but if this does not occur one can still say with confidence that the underlying processes have been modulated in a positive way.

Cartrophen differs from non-steroidal anti-inflammatories which only effects the symptoms; it has healing properties and clinical improvement is a result of this more fundamental effect. Clinical studies have demonstrated that Cartrophen has equal or superior effects to the powerful non-steroidal drug, Rimadyl. Interestingly non-steroidal’s take 1-2 weeks to reach maximum clinical efficacy, whch is similar to Cartrophen.

The questions you must ask your client is ‘do they want a disease modifying option or a pain masking therapy?’


It is rare that OA presents as an acute emergency. In the event that serious pain is observed, there should be an immediate investigation into the real underlying cause of the symptoms. As Cartrophen is a disease modifying agent, it is recommended that the pet be kept quiet and warm during the course of the therapy. Exercise should be restricted to enable the healing process to be maximised.

The analogy of resting a limb that has fractured to allow healing is relevant. There is a need to address immediate pain and discomfort, but concurrent use of NSAIDs is discouraged as it may interfere with the healing process during drug administration.

Copyright © 2016 Biopharm Australia Pty Ltd

All rights reserved

Back to top